Keywords: Nanobiotix, NBTXR3, Soft tissue sarcoma

Nanobiotix starts clinical trial with lead product for soft tissue sarcoma

Article | 15 September 2011

Print This

Nanobiotix, an emerging French nanomedicine company focused on cancer therapy, says that its lead compound, NBTXR3, has received the formal ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in